학술논문

2023 French recommendations for diagnosing and managing prepatellar and olecranon septic bursitis.
Document Type
Academic Journal
Author
Darrieutort-Laffite C; Rheumatology Department, CHU de Nantes, Nantes, France; Nantes Université, Oniris, CHU de Nantes, Inserm, Regenerative Medicine and Skeleton, RMeS, UMR 1229, 44000 Nantes, France.; Coiffier G; Rheumatology Department, Dinan Hospital, Dinan, France.; Aïm F; Orthopedic Unit and Osteoarticular Reference Center, GH Diaconesses Croix Saint-Simon, Paris, France.; Banal F; Department of Rheumatology, Centre Hospitalier Universitaire Amiens Picardie, 80054 Amiens, France.; Bart G; Internal Medicine and Rheumatology department, Percy Army Training Hospital, Clamart, France.; Chazerain P; Rheumatology Department, Groupe Hospitalier Diaconnesses Croix Saint-Simon, 75020 Paris, France.; Couderc M; Rheumatology Department, CHU Gabriel-Montpied, Clermont-Ferrand, France; Inserm/Imost, UMR 1240, Clermont-Ferrand, France.; Coquerelle P; Rheumatology Department, Béthune Hospital, Béthune, France.; Ducourau Barbary E; Medicine Department, Oreliance Health Center, Saran, France.; Flipo RM; Department of Rheumatology, CHU de Lille, Université de Lille, 59000 Lille, France.; Faudemer M; Rheumatology Department, CHU Saint-Antoine, 75012 Paris, France.; Godot S; Internal Medicine and Rheumatology department, Percy Army Training Hospital, Clamart, France.; Hoffmann C; Emergency Department, Groupe Hospitalier Diaconnesses Croix Saint-Simon, 75020 Paris, France.; Lecointe T; Orthopedic surgery Department, CHU d'Orléans, Orléans University, 45067 Orléans, France.; Lormeau C; Rheumatology Department, Niort Hospital, Niort, France.; Mulleman D; EA6295 Nano Medicines & Nano Probes Research Group, University of Tours, Department of Rheumatology, CHRU de Tours, Tours, France.; Piot JM; Rheumatology Department, Centre Hospitalier du Mans, Le Mans, France.; Senneville E; Department of Infectious Diseases, Tourcoing Hospital, Tourcoing, France.; Seror R; Rheumatology Department, AP-HP, Hôpitaux Universitaires Paris-Saclay, Hôpital Bicêtre, Le Kremlin-Bicêtre, France; Centre of Immunology of Viral Infections and Autoimmune Diseases (IMVA), Inserm U1184, Université Paris-Sud, Université Paris-Saclay, Le Kremlin-Bicêtre, France.; Voquer C; Montalembert Medical Center, Clermond-Frerrand, France.; Vrignaud A; Multidisciplinary Health Center of Conlie, Conlie, France.; Guggenbuhl P; Rheumatology Department, Hôpital Sud, CHU de Rennes, 35000 Rennes, France; Rennes University, Inserm, CHU de Rennes, Institut NUMECAN (Nutrition Metabolisms and Cancer), UMR 1317, 35000 Rennes, France.; Salliot C; Rheumatology Department, CHU d'Orléans, Orléans University, 45067 Orléans, France. Electronic address: carine.salliot@chu-orleans.fr.
Source
Publisher: Editions Elsevier Country of Publication: France NLM ID: 100938016 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1778-7254 (Electronic) Linking ISSN: 1297319X NLM ISO Abbreviation: Joint Bone Spine Subsets: MEDLINE
Subject
Language
English
Abstract
Septic bursitis (SB) is a common condition accounting for one third of all cases of inflammatory bursitis. It is often related to professional activities. Management is heterogeneous and either ambulatory or hospital-based, with no recommendations available. This article presents recommendations for managing patients with septic bursitis gathered by 18 rheumatologists from the French Society for Rheumatology work group on bone and joint infections, 1 infectious diseases specialist, 2 orthopedic surgeons, 1 general practitioner and 1 emergency physician. This group used a literature review and expert opinions to establish 3 general principles and 11 recommendations for managing olecranon and prepatellar SB. The French Health authority (Haute Autorité de santé [HAS]) methodology was used for these recommendations. Designed for rheumatologists, general practitioners, emergency physicians and orthopedic surgeons, they focus on the use of biological tests and imaging in both outpatient and inpatient management. Antibiotic treatment options (drugs and duration) are proposed for both treatment modalities. Finally, surgical indications, non-drug treatments and prevention are covered by specific recommendations.
(Copyright © 2023 Société française de rhumatologie. Published by Elsevier Masson SAS. All rights reserved.)